Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
about
Ultra-long acting insulin versus long-acting insulin for type 1 diabetes mellitusInsulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?Insulin degludec as an ultralong-acting basal insulin once a day: a systematic reviewConcentrated insulins: the new basal insulinsFatty acids as therapeutic auxiliaries for oral and parenteral formulationsTreating type 1 diabetes: from strategies for insulin delivery to dual hormonal controlClinical utility of insulin and insulin analogs.Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial.Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.Prediction of nocturnal hypoglycemia unawareness by fasting glucose levels or post-breakfast glucose fluctuations in patients with type 1 diabetes receiving insulin degludec: A pilot study.Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.Treat-to-target trials: uses, interpretation and review of concepts.Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinicalThe beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.Uncovering undetected hypoglycemic eventsInsulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetesComparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.Design of non-standard insulin analogs for the treatment of diabetes mellitusPlasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extensionFuture of newer basal insulinHypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.Insulin degludec: a significant advancement in ultralong-acting Basal insulin.Insulin degludec: pharmacokinetics in patients with renal impairment.Using albumin to improve the therapeutic properties of diabetes treatments.Improving the treatment experience for patients with type 2 diabetes: role of the nurse practitioner.Evolution of insulin development: focus on key parameters.Efficacy and safety of ultra-long-acting insulin degludec.Insulin degludec: overview of a novel ultra long-acting basal insulin.Insulin degludec: a novel basal insulin analogue.Newer insulin analogs: advances in basal insulin replacement.Insulin therapies: Current and future trends at dawn.
P2860
Q24194881-28B91741-AFB2-4BB8-A02B-4B27C857CC9DQ24624156-F61ED0A4-1287-4B03-B407-0BF33F3C578FQ24630395-B04989B1-8BE8-4058-8450-287513C4DE35Q26750438-D17EA93D-2CDE-4521-838F-68F4D7E3F391Q26828805-D060E56D-0E30-49EA-9EFF-339957649C34Q26853250-E1FE8FA2-33CD-4AEE-8EA8-5C3546907CC3Q30429358-FAE565E0-DDE4-4CFB-99DB-88FAF9EC9E0AQ33603473-6EE03C2D-99F9-46C9-9F31-12D6085BFFD8Q33607759-2A487AC7-D2FC-41C3-8850-943FB4758084Q33879458-131F3316-6702-4858-BF68-794CAD76C495Q34311240-F86590EB-6B92-4C9A-A9B2-3B94EF0752BCQ34540987-1670C8AC-556E-4A97-A5E6-8D038D9120BDQ34543035-D9D0B3AF-0EAA-4DB4-9974-7C88DD7F5929Q34691408-84E0ED71-2D82-4797-866B-F82B225AB5DEQ35457098-BFC791E3-E8B3-45AE-BD1F-077CD205250DQ35921474-C3E01F7B-30CA-477A-8284-E10D2225621DQ35922100-9B096DD5-68BC-4B59-B457-9FDF67C18BE9Q35988978-0C88A585-12FF-4893-9057-2480F669B250Q36097341-D4E90CCB-B6E9-4E7F-89B8-9538040B20EEQ36103732-C7D38C11-369B-4E63-9CDC-86D0F69790E7Q36158944-8B07BE83-E156-49E8-A6F3-13281E34FD64Q36334638-A3510443-12A5-4E1B-A417-9CEFDBB73DC8Q36374363-9BC8AE8F-74C0-4816-8AB5-039DF5E154BBQ36554243-A0D16B45-87CA-4347-AA26-1269E7C87DD8Q36629179-B5F998DA-0A4C-4AC9-AF07-28468005906AQ36730246-739076C3-85F3-4F33-98AA-538CC551FF9EQ36930701-8CCC50EC-D2A4-4AB0-B663-5EBF057C3A08Q37119978-E4E5E66C-6A20-4AF9-8D73-1F5B18495E30Q37374117-FA27AA2D-D47D-4DA6-A18D-3DEFF21AA666Q37421683-9538C055-EF69-4DFC-A14E-0D2B03751FB3Q37468486-B2516095-5CE9-4390-A968-A8EF57C48995Q37506526-5010A879-5DFF-4839-BF49-512FEE5261EAQ37910976-EBEF445E-3725-4BFE-A17A-6EDCA81A1F5AQ38008007-A39C84EB-80AC-4EF3-8C17-8D2BB8AFF39EQ38030454-6FFE3278-178E-4BF6-B2F1-244A7829330FQ38059486-1863C239-6C2C-4A9B-9B6B-3470D918C40AQ38067424-C2C91623-2320-42D9-8152-E3404AF353D0Q38079527-457F01CA-F01D-49B1-9272-1E5DAA145CC7Q38085332-69958AF4-8FEE-4B78-917A-D8D2B3D6BA7EQ38089594-63756FD8-07A7-462A-8A69-50DD5AE65122
P2860
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Insulin degludec in type 1 dia ...... ompared with insulin glargine.
@ast
Insulin degludec in type 1 dia ...... ompared with insulin glargine.
@en
Insulin degludec in type 1 dia ...... ompared with insulin glargine.
@nl
type
label
Insulin degludec in type 1 dia ...... ompared with insulin glargine.
@ast
Insulin degludec in type 1 dia ...... ompared with insulin glargine.
@en
Insulin degludec in type 1 dia ...... ompared with insulin glargine.
@nl
prefLabel
Insulin degludec in type 1 dia ...... ompared with insulin glargine.
@ast
Insulin degludec in type 1 dia ...... ompared with insulin glargine.
@en
Insulin degludec in type 1 dia ...... ompared with insulin glargine.
@nl
P2093
P2860
P356
P1433
P1476
Insulin degludec in type 1 dia ...... compared with insulin glargine
@en
P2093
Anthony P Roberts
Karsten Lyby
Kåre I Birkeland
Lars A Endahl
Luigi F Meneghini
Philip D Home
Robert E Ratner
Thue Johansen
Ulrich Wendisch
P2860
P304
P356
10.2337/DC10-1925
P407
P577
2011-01-26T00:00:00Z